Dr. John F. Valliant, Associate Professor, Department of Chemistry (Radiochemistry).
The objective of Dr. Valliant's work is to discover and implement new platform technologies for the preparation of targeted molecular imaging agents. Each imaging probe, or radiopharmaceutical, consists of a biologically active molecule which dictates the in vivo behaviour of the drug, and a radioactive isotope that can be detected by external cameras to determine the in vivo location of the probe. By visualizing specific biochemical processes in this way, it is possible to non-invasively detect and assess a variety of disease states. Though based in synthetic organic, inorganic and radiochemistry, this research program spans a number of fields including chemical biology and nuclear medicine. The radiochemistry experiments are conducted in the HLLF using a variety of SPECT and PET radioisotopes, as well as I-125 that is produced at MNR.
In addition to leading an active academic research group, Dr. Valliant is also the founder, Scientific Director and CEO of the Centre for Probe Development and Commercialization (CPDC), a Centre of Excellence for Commercialization and Research focusing on the development of molecular imaging probes.
For more information, click here.